Nemaura Medical Inc. NMRD Archives - Page 5 of 6

ThursdayOct 28, 2021 11:59 am

QualityStocksNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Stands Distinct in Patient Support

Nemaura Medical (NASDAQ: NMRD), a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, pays close attention to essential information and research that impacts the successful implementation of its solutions. Recently, the company tweeted about a study published by Dove Medical Press that included a survey of 105 participants with type 2 diabetes. The report indicated that most participants were interested in using electronic methods to communicate more with their doctors between visits. “These findings are particularly interesting to Nemaura, which has developed a proprietary technology that replaces traditional invasive methods of glucose monitoring that…

TuesdayOct 26, 2021 9:37 am

Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) Target Diabetes Tech

The world’s largest and most powerful tech companies –Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) – are targeting an opportunity in health care that’s just too big to ignore – diabetes. Almost a third of the entire U.S. population – more than 100 million people in this country alone – are living with diabetes or are at high risk for the disease. Diabetes makes it difficult for the body to process sugar (glucose) and can lead to serious health issues and death. With $1 of every $4 of health care costs in the U.S. now spent on…

FridayOct 22, 2021 12:25 pm

QualityStocksNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Facilitating Improved Diabetes and Prediabetes Management

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing diagnostic devices and supporting personalized lifestyle coaching programs. Its flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor designed to help people with diabetes and prediabetes manage their glucose levels. “Over 420 million people globally are currently living with diabetes, with prediabetic cases totaling almost three times that number,” reads a recent article. “Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.” To view…

MondayOct 18, 2021 12:36 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Announce Beta Launch of Proprietary ‘MiBoKo’ Metabolic Health Program

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently announced the beta launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores US diabetes-related healthcare expenditures totalled $760 billion in 2019 alone, equating to an annual spend of over $9,000 per diabetic patient Nemaura Medical (NASDAQ: NMRD) is a cutting-edge medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company recently carried out the beta launch of MiBoKo, a new proprietary metabolic health program…

FridayOct 15, 2021 11:06 am

QualityStocksNewsBreaks – Why Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Founded in 2011, the company set out to create a single platform technology to measure blood markers at the surface of the skin. Since then, it has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and wellbeing. “Its flagship product, sugarBEAT(R), is a wearable, non-invasive, and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and pre-diabetes manage their glucose levels. Insulin users…

WednesdayOct 06, 2021 9:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Harnesses the Power of Patient-Provider Communication

NMRD has developed a proprietary technology that replaces traditional invasive methods of diagnosis and healthcare observation procedures Report notes that study participants are interested in using electronic methods to communicate more with their doctors between visits Better communication between patients and their healthcare providers impacts adherence to prescribed treatment According to a report published in Dove Medical Press, communication between patients and their physicians has a notable impact on adherence to prescribed treatment and improved health care (https://ibn.fm/ZMYMQ). As a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, Nemaura Medical (NASDAQ: NMRD) pays special…

TuesdayOct 05, 2021 1:03 pm

QualityStocksNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming LD Micro Main Event

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be featured at the 14th annual LD Micro Main Event conference; the conference will be a virtual event. As part of the company’s presence at the conference, NMRD CEO Faz Chowdhury, PhD, will present an overview of the company. That presentation is scheduled for Oct. 13, 2021, at 10 a.m. ET. To view the full presentation, visit https://ibn.fm/QtCSC To view the full press release, visit https://ibn.fm/l0HsS About Nemaura Medical Inc. Nemaura Medical…

WednesdaySep 29, 2021 10:42 am

QualityStocksNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Beta Launch of MiBoKo

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application. According to the update, Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will discuss MiBoKo in more detail during his corporate presentation scheduled for today, Sept. 29, 2021, at 11:10 a.m. ET during the Benzinga Healthcare Small Cap Conference. Investors can access the presentation by registering for the conference at https://ibn.fm/tbmt0. “A person’s response to…

MondaySep 27, 2021 1:19 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Reveals Attendance at This Year’s H.C. Wainwright Global Investment Conference

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021 Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025 Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs; the company’s flagship product, the sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor designed…

MondaySep 27, 2021 12:34 pm

QualityStocksNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription only medicines that are widely prescribed for people with type 2 diabetes. MSW-DP has been granted global rights to the sugarBEAT(R) non-invasive CGM devices and sensors, to be provided solely as duo packs with these medicines, under the terms of the agreement, which Nemaura will…

Site Search

Company Search

Tag: Nemaura Medical Inc. NMRD